Literature DB >> 31692220

Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients.

Kazuo Notsumata1, Yoshimoto Nomura1, Akihiro Tanaka1, Teruyuki Ueda1, Taku Sanada1, Hiroyuki Watanabe1, Daishu Toya1.   

Abstract

Entities:  

Keywords:  chronic hepatitis B; entecavir; fibroblast growth factor 23; phosphorus metabolism; renal tubular dysfunction; tenofovir alafenamide; urinary liver-type fatty acid-binding protein

Year:  2020        PMID： 31692220     DOI： 10.1111/hepr.13451

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  2 in total

1.  Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide.

Authors:  Takuma Okamura; Tatsuki Ichikawa; Hisamitsu Miyaaki; Satoshi Miuma; Yasuhide Motoyoshi; Mio Yamashima; Shinobu Yamamichi; Makiko Koike; Yusuke Nakano; Tetsurou Honda; Hiroyuki Yajima; Osamu Miyazaki; Yasutaka Kuribayashi; Tomonari Ikeda; Naota Taura; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2021-11-24

Review 2.  Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.

Authors:  Young-Suk Lim; Wai-Kay Seto; Masayuki Kurosaki; Scott Fung; Jia-Horng Kao; Jinlin Hou; Stuart C Gordon; John F Flaherty; Leland J Yee; Yang Zhao; Kosh Agarwal; Pietro Lampertico
Journal:  Aliment Pharmacol Ther       Date:  2022-02-17       Impact factor: 9.524
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.